Physician profile
Lance A Hansen
NPI 1861620262
$1,726.82
in general payments reported to CMS, 2019-2025
25 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $134 · 2021: $244 · 2022: $363 · 2023: $196 · 2024: $263 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.57 | 2021-2025 | |
| Novo Nordisk INC | $170.52 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.70 | 2019-2021 | |
| Lilly USA, LLC | $109.49 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $77.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $73.44 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $59.90 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $59.63 | 2024-2025 | Voquezna |
| Amgen INC. | $46.36 | 2020-2021 | |
| Abbott Laboratories | $41.18 | 2021-2022 | |
| Pfizer INC. | $38.67 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.23 | 2019-2022 | |
| Dexcom, INC. | $24.68 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.87 | 2024 | Gvoke Hypopen |
| Corium, LLC | $23.54 | 2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.06 | 2023 | Trintellix |
| Exact Sciences Corporation | $21.38 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $20.36 | 2022 | |
| Tris Pharma INC | $20.17 | 2024 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $18.56 | 2023 | Inspire |
| Astellas Pharma US INC | $17.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.16 | 2024 | Dupixent |
| Medtronic, INC. | $12.03 | 2022 | |
| Glaxosmithkline, LLC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.